RT Journal Article
T1 Effectiveness of COVID-19 vaccine booster in the general population and in subjects with comorbidities. A population-based study in Spain
A1 Mallah, Narmeen
A1 Pardo Seco, Jacobo José
A1 López Pérez, Luis Ricardo
A1 González Pérez, Juan Manuel
A1 Rosón Calvo, Benigno
A1 Otero Barrós, María Teresa
A1 Durán Parrondo, Carmen
A1 Nartallo Penas, Victoria
A1 Mirás Carballal, Susana
A1 Rodríguez Tenreiro, Carmen
A1 Rivero Calle, Irene
A1 Gómez Carballa, Alberto
A1 Salas Ellacuriaga, Antonio
A1 Martinón Torres, Federico
K1 COVID-19 booster vaccine effectiveness
K1 Comorbidities
K1 Population-based study
K1 SARS-CoV-2
K1 Spain
AB Background: Research on the effectiveness of COVID-19 booster-based vaccine schedule is ongoing and real-world data on vaccine effectiveness (VE) in comorbid patients are limited. We aimed to estimate booster dose VE against SARS-CoV-2 infection and COVID-19 severity in the general population and in comorbid patients. Method: A retrospective test-negative control study was undertaken in Galicia-Spain (December 2020–November 2021). VE and 95% confidence interval (CI) were estimated using multivariate logistic regression models. Results: 1,512,415 (94.13%) negative and 94,334 (5.87%) positive SARS-CoV-2 test results were included. A booster dose of COVID-19 vaccine is associated with substantially higher protection against SARS-CoV-2 infection than vaccination without a booster [VEboosted = 87% (95%CI: 83%; 89%); VEnon-boosted = 66% (95%CI: 65%; 67%)]. The high VE was observed in all ages, but was more pronounced in subjects older than 65 years. VE against COVID-19 severity was analyzed in a mixed population of boosted and non-boosted individuals and considerable protection was obtained [VE: hospitalization = 72% (95%CI: 68%; 75%); intensive care unit administration = 83% (95%CI: 78%; 88%), in-hospital mortality = 66% (95%CI: 53%; 75%)]. Boosted comorbid patients are more protected against SARS-CoV-2 infection than those who were non-boosted. This was observed in a wide range of major diseases including cancer (81% versus 54%), chronic obstructive pulmonary disease (84% versus 61%), diabetes (84% versus 65%), hypertension (82% versus 65%) and obesity (91% versus 67%), among others. Conclusions: A booster dose of COVID-19 vaccine increases the protection against SARS-CoV-2 infection and COVID-19 severity in the general population and in comorbid patients.
PB Elsevier
YR 2022
FD 2022
LK http://hdl.handle.net/10347/29474
UL http://hdl.handle.net/10347/29474
LA eng
NO Environmental Research 215 (2022) 114252
NO This work was supported by Framework Partnership Agreement between the Consellería de Sanidad de la XUNTA de Galicia and GENVIP-IDIS-2021–2024 (SERGAS-IDIS March 2021; Spain); and consorcio Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CB21/06/00103; F.M-T), DIAVIR (Instituto de Salud Carlos III (ISCIII)/DTS19/00049/Cofinanciado FEDER; Proyecto de Desarrollo Tecnológico en Salud), Resvi-Omics (Instituto de Salud Carlos III (ISCIII)/PI19/01039/Cofinanciado FEDER), BI-BACVIR (PRIS-3; Agencia de Conocimiento en Salud (ACIS)—Servicio Gallego de Salud (SERGAS)—Xunta de Galicia; Spain), Programa Traslacional COVID-19 (ACIS—Servicio Gallego de Salud (SERGAS)—XUNTA de Galicia; Spain) and Axencia Galega de Innovación (GAIN; IN607B 2020/08—XUNTA de Galicia; Spain) [A.S]; and ReSVinext (Instituto de Salud Carlos III (ISCIII)/PI16/01569/Cofinanciado FEDER), Enterogen (Instituto de Salud Carlos III (ISCIII)/PI19/01090/Cofinanciado FEDER), and Axencia Galega de Innovación (GAIN; IN845D 2020/23—Xunta de Galicia; Spain) [F.M-T]
DS Minerva
RD 1 may 2026